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ABSTRACT

Background/Aims

This study characterized the safety and pharmacologic properties of AVI-005, a novel glycosylated recombinant
human interferon-α2b produced from the egg whites of chickens transfected with human cDNA.

Methods

Sixteen healthy volunteers received single rising doses of AVI-005. A subcutaneous dose of 0.5, 1.66 or 5
million international units (MIU) was administered. A randomized parallel comparator group of 10 subjects
received 5 MIU unglycosylated IFN-α2b (Intron A). The pharmacokinetic parameters t1/2, Tmax, Cmax, AUC0-24
hr,

Vd, and clearance were compared between AVI-005 and unglycosylated IFN-α2b.

Results

At equipotent doses, AVI-005 generated a larger AUC0-24hr than the control interferon. Pharmacodynamic
markers of neopterin and β2 microglobulin were similar between the two treatments. These markers
demonstrated dose dependent increases to AVI-005. Pharmacodynamic measures of mRNA expression of PKR
and 2’5’ oligoadenylate synthetase demonstrated a response to treatment with AVI-005. Adverse events were
qualitatively and quantitatively similar in both groups.

Conclusion

AVI-005 demonstrates biologic activity and pharmacokinetic properties in humans that support further
development.
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INTRODUCTION
The interferons (IFNs) are immunomodulatory cytokines with antiviral and antitumor properties. (1). IFN-α is
produced by leucocytes in response to viral infections. (2) Interferon -α2b (IFN-α2b) is an alpha interferon
subtype used in the treatment of chronic hepatitis B and C, malignant melanoma, follicular (non-Hodgkin's)
lymphoma, AIDS-related Kaposi's sarcoma, condylomata acuminata, and hairy cell leukemia. In humans, the
native form of IFN-α2b consists of a single polypeptide chain of 165 amino acids with O-linked glycosylation
at residue threonine-106. There are presently two FDA-approved recombinant IFN-α2b products, Intron A, and
PEG-Intron (Schering-Plough, Kenilworth, NJ). Intron A is bacterial-derived non-glycosylated protein with an
amino acid sequence identical to the natural IFN-α2b. PEG-Intron is comprised of the same underlying
polypeptide chain linked to polyethylene glycol (PEG). This synthetic glycosylation provides improved
efficacy with once-weekly administration. (3)

The current standard of care for the treatment of hepatitis C virus (HCV) infections is an interferon plus
ribavirin. (4) Approximately 55% of patients with the most prevalent form of HCV do not respond to currently
available interferon therapeutics. According to the World Health Organization, 200 million people, or 3% of
the world's population, are infected with HCV with 170 million chronic carriers globally at risk of developing
liver cirrhosis and hepatocellular carcinoma. (5) The Third National Health and Nutrition Examination Survey
(NHANES III) found that 1.8 percent of Americans (3.9 million) have been infected with HCV. (6) An
additional 400 million people worldwide are chronically infected with hepatitis B virus (HBV). (7) Thirty
percent of HBV patients who tolerate interferon therapy have successful response. (8) Despite proven efficacy,
the high cost of producing IFN-α2b by present methods places this treatment out of reach of the large majority
of patients worldwide who suffer from these interferon-remediable infections.
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AVI-005 is a transgenic human IFN-α2b produced by purification of chicken egg whites from hens transfected
with human IFN-α2b cDNA. The AVI-005 manufacturing process involves 1) construction of a vector carrying
the human IFN-α2b transgene, 2) insertion of IFN-α2b transgene into the chicken genome using embryo
transduction technique, 3) screening of hatched birds to identify birds carrying the human transgene 4) breeding
and characterization of transgenic birds to identify a founder (G1), 5) characterization of the G1 founder and its
subsequent generations to confirm stable transmission of the IFN-α2b transgene through multiple generations
and 6) harvesting and purification of the AVI-005 protein from the egg white. An advantage of this process is
the ability to generate relatively large amounts of transgenic protein, which may translate into reduced
production costs of recombinant human IFN-α2b. The amino acid structure of AVI-005 matches that of the
native human IFN α2b. AVI-005 differs from the existing commercially available IFN-α2b products in that the
threonine residue at position 106 is glycosylated with carbohydrate chains making it chemically identical to
endogenous human IFN-α2b.

The goal of this first-in-human study was to characterize the safety, tolerability, pharmacokinetics and
pharmacodynamics of AVI-005 in healthy human volunteers upon intramuscular administration of rising single
doses, and to assess similarity to the existing commercially available IFN α2b product Intron A, henceforth
described as “control interferon”.

PATIENTS AND METHODS

Subjects
Twenty eight healthy volunteers were enrolled in this study. Informed consent was obtained from each subject
prior to any study procedures. The study protocol conforms to the ethical guidelines of the Declaration of
Helsinki as reflected in approval by the Institutional Review Board of Thomas Jefferson University. Subjects
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were deemed to be in good health on the basis of medical history, physical examination, laboratory values, and
electrocardiograms (ECG). No subjects used prescription or over-the counter medications 2 weeks prior to
study start. The mean age of the subjects was 31 years (range 19-49). Twenty-two (79%) of the subjects were
male. Seventeen (61%) subjects were white, 8 (28%) were black and 3 (11%) were Hispanic.

Study Design
This was an open label, single rising dose study of intramuscular AVI-005 in healthy subjects. At the highest
dose level, subjects were randomized to either AVI-005 or an equivalent dose of control interferon in a parallel
design. The treatment groups were as follows: 1) 0.50 million units equivalent of AVI-005 (4 subjects), 2) 1.66
million units equivalent of AVI-005 (4 subjects), and 3) 5.00 million units equivalent of AVI-005 or control
interferon (10 subjects in each treatment arm). The selection of the dose was based on preclinical data in
primates employing AVI-005 doses of 0.13, 0.9, and 4.7 µg/kg which correspond, respectively, to 0.3, 2.2, and
11 times the human doses used in the current trial. The equivalency of AVI-005 doses to control interferon
doses was determined by a bioactivity assay calibrated with one used for control interferon using a defined
reference standard.

Each subject received a thorough physical exam, clinical laboratory safety assessment (hematology,
electrolytes, liver function tests, and urinalysis) and ECG during screening. Female subjects had negative
serum pregnancy test during screening and a negative urine pregnancy test the morning of study drug
administration. Study subjects received a single intramuscular injection in the left buttock followed by
pharmacokinetic and pharmacodynamic sampling. ECG’s were performed at screening, within 1 hour of
dosing, at 8 hours, and 3 and 30 days post study drug administration. Injection sites were observed for signs of
irritation or inflammation.
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Pharmacokinetics
Blood for AVI-005 pharmacokinetics was drawn at baseline and 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, 24, 48, 72,
96, 120 and 144 hours after drug administration. Subjects receiving control interferon had blood drawn for
pharmacokinetics at predose; and 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 12, and 24 hours after drug administration.
Serum levels of AVI-005 and control interferon were determined using an interferon alpha specific ELISA. A
96-well plate was coated with an interferon alpha specific monoclonal antibody (Chemicon, Temcula, CA).
Following blocking of the non-coated surface area with bovine serum albumin (Sigma, St. Louis, MO), the
appropriate sample or standard was added. Captured interferon-α2b was detected with a secondary polyclonal
anti-IFN alpha antibody which was indicated by a third alkaline phosphatase-conjugated antibody. The amount
of IFN-α2b in a tested sample was indicated by the increase in the optical density at 450 nm after addition of
alkaline phosphatase substrate. Concentration was calculated by interpolation using a standard curve generated
with either AVI-005 internal standard or control interferon.

Pharmacodynamics
Pharmacodynamic analysis consisted of serial determination of serum analytes neopterin and β2 microglobulin
and of messenger RNA (mRNA) expression of the interferon-inducible protein kinase (PKR) and 2’5’
oligoadenylate synthetase (OAS). Neopterin, a pyrazinopyrinidine compound, is produced by macrophages
after induction by interferons and serves as a marker of cellular immune system activation. (9) β2
microglobulin is a protein found on the surface of many cells, including white blood cells. Increased production
of white blood cells, as seen with interferon administration, causes β2 microglobulin levels in the blood to
increase. PKR is an interferon-inducible serine/threonine protein that is part of the innate immune response and
inhibits viral replication. Its mechanism of action involves RNA-dependent autophosphorylation, leading to
inhibition of translation. (10, 11) OAS is one of many genes encoding enzymes with antiviral activities. It is

6

Patel

AVI-005 (IFN-α2b) in healthy volunteers

important for antiviral response, and its activity is required by cells to activate the endonuclease RNase L,
which degrades RNA. (12).

Blood for measurement of neopterin and β2 microglobulin was collected at predose, 24, 48, 72, 96, 120, and
144 hours post dose. Five subjects in the control interferon group had these analytes measured only at predose,
24, 48, and 144 hours. Blood for PKR and OAS mRNA was collected using a protease inhibitor RNALater
(Ambion, Inc., Austin, TX) or Paxgene collection tubes (Qiagen, Valencia, CA) at predose, 8, 12, 24, 48, and
72 hours post study drug administration. Five subjects who received the control interferon did not have a 72hour sample for PKR or OAS.

Pharmacokinetic Data Analysis
Pharmacokinetic analysis was performed using WinNonLin Enterprise version 4.1 (Pharsight Inc., Mountain
View, CA). A non-compartmental approach was employed. Analysis of pharmacokinetics was performed out
to 24 hours. Area under the curve (AUC) was determined using the linear trapezoidal rule. A terminal
elimination constant was determined if judged appropriate by visual examination of the terminal time points. In
cases where a terminal elimination could not be determined, only AUC0-24 hr, maximum concentration (Cmax),
and time to maximum concentration (Tmax) were generated. For those in whom a reliable terminal elimination
constant could be determined, half life, clearance, and volume of distribution were determined. Analysis of data
from subjects receiving AVI-005 0.5 MIU was not performed due to concentrations below the limit of
quantification.

Statistical Methods
Pharmacokinetics
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AUC and Cmax values were natural log-transformed. Means, standard deviations, minimums, maximums, and
medians were calculated for each dose level and treatment group. Arithmetic means were back-transformed (by
taking anti-logs) to obtain geometric means and geometric mean ratios. The 90% confidence intervals for
geometric means were calculated for AVI-005 5 MIU and control interferon groups.

At the 5 MIU dose level, an unequal variances t-test (with Satterthwaite degrees-of-freedom) was used to
compare AVI-005 and control interferon for parameters AUC0-24 hr and Cmax. Ratios (AVI-005/control
interferon) of geometric means were calculated by back-transforming the difference of means, and a 90%
confidence interval was calculated for this ratio. Residuals were computed and examined for normality.
Summary statistics (minimum, maximum, standard deviation, and median or harmonic mean) were computed
for half-life (harmonic mean) and Tmax (median) values.

Pharmacodynamics
Pharmacodynamic analysis consisted of serial determination of serum analytes neopterin and β2 microglobulin
and mRNA expression of PKR and OAS. These were analyzed as fold increase from the baseline for each, with
determination of an area under the fold increase curve and Cmax, the maximum increase from baseline.
Geometric mean ratios of AUC0-144 hr and Cmax were compared, with 90% confidence intervals calculated for
AVI-005 5 MIU and control interferon groups. Measurement of neopterin and β2 microglobulin was performed
at predose, 24, 48, 72, 96, 120, and 144 hours post dose. One half of the subjects in the control interferon group
had these analytes measured only at predose, 24, 48, and 144 hours. One subject was not included in the
analysis of neopterin and β2 microglobulin due to a very high baseline neopterin. This subject did not have any
evidence of viral infection at the time of dosing, but did develop some symptoms of upper respiratory tract
infection in the subsequent 30 days, which may account for this finding.
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Data points for neopterin and β2 microglobulin for the 120 hour time point were not available for one subject,
and data for the 144 hour time point were not available for 4 subjects. For this reason, both AUC0-120 hr and
AUC0-144 hr were determined. Examination of the geometric mean ratio between AVI-005 5 MIU and control
interferon was performed on AUC0-144 hr and Cmax. The AUC0-120 hr was used to compare different AVI-005 dose
levels.

PKR and OAS mRNA samples were assayed at predose, 8, 12, 24, 48, and 72 hours. Five subjects who
received control interferon did not have a 72 hour sample for PKR or OAS. Examination of the geometric mean
ratio between AVI-005 5 MIU and control interferon was performed on AUC0-72 hr and Cmax.

RESULTS

Pharmacokinetics
Table 1 shows the PK parameters of the 3 measured groups. Half life, volume of distribution and clearance for
the AVI-005 1.66 MIU were not presented because these parameters could be estimated for only one subject of
four receiving this treatment. For groups receiving 5 MIU of AVI-005 or control interferon, these parameters
were generated only in whom reliable terminal elimination phases could be determined. Interferon
concentrations could not be reliably quantified in one subject receiving control interferon. This subject did,
however, mount pharmacodynamic responses suggestive of interferon effect in all 4 analytes measured.

A comparison of the pharmacokinetic parameters of AVI-005 and control interferon at the 5 MIU dose is
presented in Table 2. AUC0-24 hr and Cmax for the AVI-005 group was approximately 2 fold greater than in the
control interferon group. It should be noted that both AVI-005 and control interferon were dosed on an activity
(MIU) basis, though analytic characterization was performed on mass of interferon. To correct for the
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differences in mass of interferon administered, individual subject parameters of AUC0-24 hr and Cmax were
divided by the mass of drug administered. Normalization of the AUC0-24 hr and Cmax data to mass of drug
administered decreased the difference between the two treatments, although AUC0-24 hr of AVI-005 remained
significantly larger than that of control interferon, (p=<0.001). The 90% confidence intervals for both dosenormalized AUC0-24 hr and Cmax extended higher than the customary upper limit pharmacokinetic geometric
mean ratio bound of 1.25 for bioequivalence.

Pharmacodynamics
Neopterin AUC and Cmax rose with increasing administered dose of AVI-005 (Figure 1). β2 microglobulin
demonstrated a similar pattern of dose-dependent increase in AUC and Cmax (Figure 2). At the 5 MIU dose,
control interferon and AVI-005 had comparable neopterin and β2 microglobulin AUC0-144 hr and Cmax (Table 3).
The only statistically significant finding was an increase of control interferon β2 microglobulin in Cmax. For all
treatment groups, there was an increase in OAS and PKR over baseline values (Figures 3 and 4). However,
there was no appreciable dose relationship of AVI-005 to induction of either OAS or PKR. Control drug
generated a larger OAS AUC0-72 hr and Cmax compared to AVI-005 5 MIU, though the confidence intervals
around the point estimate of the geometric mean ratios was large.(Table 4) Differences in PKR between each of
these treatments was less, but there remained a fair amount of intersubject variability response.

Safety Results
Twenty seven of the 28 subjects reported at least 1 adverse event. Threee subjects in the AVI-005 0.5 MIU
group reported adverse events. Four subjects in the AVI-005 1.66 MIU group reported adverse events. Ten
subjects in the AVI-005 5 MIU, as well as 10 subjects in the control interferon group reported adverse events.
A summary of adverse events is presented in Table 5..
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DISCUSSION
This study describes the first human experience with AVI-005, an avian derived, human IFN-α2b. Unlike the
presently commercially available IFN-α2b products, Intron A (control interferon) and PEG Intron, AVI 005 has
glycosylation that endows the drug with a structure very similar to the endogenously produced IFN-α2b. In this
rising single dose phase 1 study, AVI-005 demonstrated a safety profile that was similar to that of an equivalent
unit dose of control interferon, with no unanticipated toxicities observed.

Biological markers were measured to assess the in vivo pharmacologic response to AVI-005. Though a direct
dose:response relationship has not always been reported, there is consensus that the markers used in this study
demonstrate biological response to interferons. (3, 13-17). There was an increase in the pharmacodynamic
response markers of neopterin and β2 microglobulin to increasing doses of AVI-005, though the small number
of subjects in the lower dose ranges and sequential dose escalation design precluded a formal assessment of
dose response linearity. Though AVI-005 clearly induced OAS and PKR mRNA translation, there did not
appear to be as clear a relationship in magnitude of change from baseline to dose administered. It should also
be noted that the present study differs from others in the use of mRNA expression of OAS and PKR, rather than
actual measurement of these proteins, though it can be inferred that the two should be linked. In addition to
measured pharmacodynamic responses, there was also a dose-related increase in adverse events, which also
supports the biologic activity of AVI-005. In contrast to the dose dependency of most of the pharmacodynamic
responses, there was a lack of apparent pharmacokinetic dose response. This is likely a function of small
number of subjects in the AVI-005 1.66 MIU group, drug concentrations near the lower limit of quantification
in this group and a large degree of intersubject variability.

While there were no a priori equivalence or superiority hypotheses tested, pharmacokinetic and
pharmacodynamic comparisons between AVI-005 and control interferon can be made. The Tmax was similar for
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both drugs, suggesting a similar rate of distribution or uptake from site of intramuscular injection, though
formal comparisons of relative bioavailability could not be determined since administration of drug by the
intravenous route was not performed. At a comparable dose of control interferon on an activity basis, AVI 005
demonstrates greater systemic exposure to mass of drug, as measured AUC0-24 hr. This difference was
decreased, but remained to some degree, after normalization for mass of drug administered. AVI-005 and
control interferon can not be considered bioequivalent by strict pharmacokinetic standards, as the 90%
confidence intervals of the geometric mean ratios of the two drugs for AUC0-24 hr and Cmax lie outside of the
generally accepted 0.8-1.25 bounds and the study was not conducted in a crossover design in the same
individual. Direct statistical comparisons of half life, volume of distribution and clearance between the two
treatments are not appropriate due to the inability to measure a terminal elimination phase in a number of
individuals, as described earlier. However, it can be hypothesized that the more glycosylated conjugation of
AVI-005 probably does not confer the increase in half life bestowed by polyethylene glycol conjugation, as
seen with PEG-Intron.

There were no protocol-specified a priori pharmacodynamic bounds to compare AVI-005 and control
interferon. However, using bioequivalence bounds of 0.5-2.0 for the geometric mean ratio between the two
drugs, there did appear to be a comparable response in the markers of neopterin and β2 microglobulin. For the
pharmacodynamic markers of OAS transcription, control interferon generated a larger response than AVI-005,
while the opposite was true for PKR. However, it should be noted that the intersubject variability for OAS and
PKR were large, making any firm conclusion about the relative potency of each drug on these markers difficult.
In addition, the sensitivity of these markers to discriminate relative biologic potency, nor the validity of these
markers as surrogate endpoints for clinical efficacy, have not been definitively established
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In conclusion, a similar dose of the avian- produced human IFN-α2b AVI-005 generates a larger AUC0-24hr
than the control interferon Intron A, a commercially available recombinant interferon -α2b with years of
clinical experience and proven efficacy. AVI-005 has a safety profile with a single dose that appears to be
comparable to that of control interferon, and generates a similar pharmacodynamic response when administered
in an equipotent dose. It is not known if the glycosylation of AVI-005 provides any advantages compared to
non-glycosylated versions with multiple doses in patients with interferon-remediable disease. Given the
potential reduced cost of production of this product compared to standard interferons, AVI-005 may expand the
use of IFN-α2b to populations in the world whom at the present time do not have access to this product.
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Table 1. Summary of Mean Values of Each of the Treatment Groups
AVI-005
1.66 MIU
Mean
SD
NDd
NDe
10a
NA
239
124
3000
1810

AVI-005
5 MIU
Mean
SD
7.1 b
2.0
a
5
NA
237
93.5
2720
1250

Control Interferon
5 MIU
Mean
SD
6.1 c
2.4
a
7
NA
122
52
1090
321

Parameter
Unit
Half life
hr
Tmax
hr
Cmax
pg/mL
AUC0-24 hr
hr*pg/mL
Volume of
Distribution
L
NDd
NDe
114 b
43
154 c
55
d
e
b
c
Clearance
L/hr
ND
ND
12
6
18
5
a
Median
b
Determined from 6 individuals
c
Determined from 5 individuals
d
Half life, Volume of Distribution and Clearance were not presented because these parameters could be
estimated for only one subject of four receiving this treatment
e
Missing data
NA= non-applicable
ND= not done
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Table 2. Geometric Mean Ratios of AVI-005 5 MIU and Control Interferon and Geometric Mean Ratios
Normalized to Mass of Drug Administered (AUC0-24 hr and Cmax)

Parameter

Units

Ratio of Geometric
Geometric Means
Means (AVI-005/
AVI-005
Control
interferon Control Interferon) and 90%
Confidence Interval
(N = 10)
(N = 9)
2,510
1,050
2.37 (1.80, 3.13)
220
114
1.94 (1.42, 2.66)
5.00
7.00
80
55
1.46 (1.10, 1.93)
7
6
1.19 (0.87, 1.63)

AUC0-24 hr
hr•pg/mL
Cmax
pg/mL
†
Tmax
hr
AUC0-24 hr dM hr•pg/mL/ug
CmaxdM
pg/mL/ug
†
Median
dM = normalized to mass of drug administered
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Table 3. Fold Increase in β2 Microglobulin Following AVI-005 5 MIU or Control Interferon
Parameter
(units)

Pharmacodynamic
Marker

AUC0-144 hr (fold increase-hr)
Cmax (fold increase)
AUC0-144 hr (fold increase-hr)
Cmax (fold increase)

β2 microglobulin
β2 microglobulin
Neopterin
Neopterin

Geometric Means
AVI-005
Control
Interferon
(N = 10)
(N = 5)
180
200
1.6
2.0
370
402
4
5

Ratio of Geometric
Means (AVI-005/
Control Interferon) and 90%
Confidence Interval
0.92 (0.84, 1.00)
0.81 (0.71, 0.91)
0.92 (0.67, 1.27)
0.87 (0.65, 1.18)

Patel
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Table 4. Fold Induction for PKR and OAS Following AVI-005 5 MIU or Control Interferon

Parameter
(units)
OAS

AUC0-72 hr

Geometric Means
AVI-005
Control
Interferon
(N = 10)
(N = 5)
570
866

Ratio of Geometric
Means (AVI-005/
Control Interferon) and 90%
Confidence Interval
0.66 (0.32, 1.35)

(fold increase-hr)

Cmax

25

34

0.73 (0.34, 1.58)

397

344

1.15 (0.68, 1.96)

21

16

1.27 (0.67, 2.44)

(fold increase)

PKR

AUC0-72 hr
(fold increase-hr)

Cmax
(fold increase)
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Table 5. Number of Subjects with Most Common Adverse Events
AVI-005
0.5 MIU
N=4

AVI005
1.66
MIU
N=4
4

AVI005
5.0 MIU
N = 10

Control
Interferon
5.0 MIU
N = 10

3
10
10
Total Subjects with Adverse
a
Events
Adverse Event b
Pyrexia
0
0
9
10
Headache
2
3
8
8
Chills
0
0
7
8
Myalgia
0
1
3
2
Nausea
0
1
2
0
Pharyngolaryngeal pain
1
0
2
0
Pain in extremity
0
1
1
1
Back pain
0
1
0
2
0.75
1.75
3.20
3.10
Average Number of Adverse
c
Events per Subject
a
Includes subjects experiencing at least one of the most common adverse events (>10% of all subjects).
b
Multiple occurrences of the same adverse event within a subject are counted once.
c
Average is generated by dividing the total number of adverse events in a group by the number of subjects in
the respective group.
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Figure 1: Neopterin (% change from baseline)
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Figure 2: β 2 Microglobulin (% change from baseline)
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Figure 3: 2’5’ oligoadenylate synthetase (% change from baseline)
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Figure 4: Interferon-inducible protein kinase (% change from baseline)
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